CircRNA circ_0000190 inhibits the progression of multiple myeloma through modulating miR-767-5p/MAPK4 pathway

Table 1 Difference in the circRNA_0000190 expression in multiple myeloma patients grouped by clinicopathological characteristics

Clinicopathological characteristics	Number of patients	Expression of circRNA_0000190 in tissues^a	P- value
Gender
Male	21	0.74 ± 0.08	0.192
Female	26	0.58 ± 0.08	0.192
Age (year)
< 42	24	0.64 ± 0.08	0.692
≥ 42	23	0.68 ± 0.09	0.692
M protein
IgG	14	0.66 ± 0.08	0.878
IgA	13	0.61 ± 0.11
Light chain	20	0.68 ± 0.10
ISS stage
I	8	1.10 ± 0.17	< 0.0001
II	16	0.78 ± 0.08
III	23	0.42 ± 0.04
Durie-Salmon stage
I	7	1.37 ± 0.09	< 0.0001
II	10	0.85 ± 0.07
III	30	0.43 ± 0.03
Hypercalcemia
With	15	0.75 ± 0.11	0.297
Without	32	0.62 ± 0.07	0.297
Renal insufficiency
With	16	0.71 ± 0.12	0.496
Without	31	0.63 ± 0.06	0.496
Anemia
With	38	0.63 ± 0.06	0.261
Without	9	0.79 ± 0.13	0.261
Bone disease
With	29	0.66 ± 0.08	0.81
Without	18	0.66 ± 0.08	0.81
Cytogenetic abnormality
With	12	0.73 ± 0.14	0.468
Without	36	0.63 ± 0.06	0.468

^a The relative expression of circRNA_0000190 was calculated using 2^−∆∆Cq method and was shown as mean ± SE

ISSN: 1756-9966